Pharma Voice: New pipeline pathways

Repurposing existing drugs could reduce cost and time when developing new medicine, but it’s not a straightforward approach. According to a study by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge, only two per cent of new molecules entering clinical trials were ultimately launched in an area other than for which they were initially tested. “As promising as repurposing might be, basic research remains essential,” the study says.

Read the full article [pharmavoice.com]